Aeglea BioTherapeutics Investor Presentation Deck

We aim to demonstrate the following for SPY001 in the expected interim Phase 1 readout 1 2 3 4 SPYRE HALF-LIFE ENABLES Q8-12W SC MAINTENANCE DOSING BASED ON PK MODELING POTENTIAL TO ADDRESS VEDO'S SLOW ONSET OF ACTION WITH HIGHER INDUCTION EXPOSURES ESTABLISH SPY-001 HAS FAVORABLE SAFETY PROFILE AND IS WELL-TOLERATED MINIMAL TO NO IMPACT ON ADA RATES VS VEDOLIZUMAB 13

View entire presentation